BACKGROUND: Small intestinal ulcers are frequent complications of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). We present here a genetic deficiency of eicosanoid biosynthesis that illuminates the mechanism of NSAID-induced ulcers of the small intestine. METHODS: Eicosanoids and metabolites were measured by isotope dilution with mass spectrometry. cDNA was obtained by reverse transcription and sequenced following amplification with RT-PCR. RESULTS: We investigated the cause of chronic recurrent small intestinal ulcers, small bowel perforations, and gastrointestinal blood loss in a 45-year-old man who was not taking any cyclooxygenase inhibitor. Prostaglandin metabolites in urine were significantly depressed. Serum thromboxane B2 (TxB2) production was 4.6% of normal controls (P<0.006), and serum 12-HETE was 1.3% of controls (P<0.005). Optical platelet aggregation with simultaneous monitoring of ATP release demonstrated absent granule secretion in response to ADP and a blunted aggregation response to ADP and collagen, but normal response to arachidonic acid (AA). LTB4 biosynthesis by ionophore-activated leukocytes was only 3% of controls, and urinary LTE4 was undetectable. These findings suggested deficient AA release from membrane phospholipids by cytosolic phospholipase A2-alpha (cPLA2-alpha), which regulates cyclooxygenase- and lipoxygenase-mediated eicosanoid production by catalyzing the release of their substrate, AA. Sequencing of cPLA2-alpha cDNA demonstrated two heterozygous nonsynonymous single-base-pair mutations: Ser111Pro (S111P) and Arg485His (R485H), as well as a known single nucleotide polymorphism (SNP), Lys651Arg (K651R). CONCLUSIONS: Characterization of this cPLA2-alpha deficiency provides support for the importance of prostaglandins in protecting small intestinal integrity and indicates that loss of prostaglandin biosynthesis is sufficient to produce small intestinal ulcers.
BACKGROUND: Small intestinal ulcers are frequent complications of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). We present here a genetic deficiency of eicosanoid biosynthesis that illuminates the mechanism of NSAID-induced ulcers of the small intestine. METHODS:Eicosanoids and metabolites were measured by isotope dilution with mass spectrometry. cDNA was obtained by reverse transcription and sequenced following amplification with RT-PCR. RESULTS: We investigated the cause of chronic recurrent small intestinal ulcers, small bowel perforations, and gastrointestinal blood loss in a 45-year-old man who was not taking any cyclooxygenase inhibitor. Prostaglandin metabolites in urine were significantly depressed. Serum thromboxane B2 (TxB2) production was 4.6% of normal controls (P<0.006), and serum 12-HETE was 1.3% of controls (P<0.005). Optical platelet aggregation with simultaneous monitoring of ATP release demonstrated absent granule secretion in response to ADP and a blunted aggregation response to ADP and collagen, but normal response to arachidonic acid (AA). LTB4 biosynthesis by ionophore-activated leukocytes was only 3% of controls, and urinary LTE4 was undetectable. These findings suggested deficient AA release from membrane phospholipids by cytosolic phospholipase A2-alpha (cPLA2-alpha), which regulates cyclooxygenase- and lipoxygenase-mediated eicosanoid production by catalyzing the release of their substrate, AA. Sequencing of cPLA2-alpha cDNA demonstrated two heterozygous nonsynonymous single-base-pair mutations: Ser111Pro (S111P) and Arg485His (R485H), as well as a known single nucleotide polymorphism (SNP), Lys651Arg (K651R). CONCLUSIONS: Characterization of this cPLA2-alpha deficiency provides support for the importance of prostaglandins in protecting small intestinal integrity and indicates that loss of prostaglandin biosynthesis is sufficient to produce small intestinal ulcers.
Authors: Olivier Boutaud; David M Aronoff; Jacob H Richardson; Lawrence J Marnett; John A Oates Journal: Proc Natl Acad Sci U S A Date: 2002-05-14 Impact factor: 11.205
Authors: David H Adler; Joy D Cogan; John A Phillips; Nathalie Schnetz-Boutaud; Ginger L Milne; Tina Iverson; Jeffrey A Stein; David A Brenner; Jason D Morrow; Olivier Boutaud; John A Oates Journal: J Clin Invest Date: 2008-06 Impact factor: 14.808
Authors: Syed Haq; Heiko Kilter; Ashour Michael; Jingzang Tao; Eileen O'Leary; Xio Ming Sun; Brian Walters; Kausik Bhattacharya; Xin Chen; Lei Cui; Michele Andreucci; Anthony Rosenzweig; J Luis Guerrero; Richard Patten; Ronglih Liao; Jeffery Molkentin; Michael Picard; Joseph V Bonventre; Thomas Force Journal: Nat Med Date: 2003-07 Impact factor: 53.440
Authors: Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Greg Hough; Georgette M Buga; Jan Danciger; Alan M Fogelman Journal: J Lipid Res Date: 2011-12-13 Impact factor: 5.922
Authors: Rongsong Li; Kaveh Navab; Greg Hough; Nancy Daher; Min Zhang; David Mittelstein; Katherine Lee; Payam Pakbin; Arian Saffari; May Bhetraratana; Dawoud Sulaiman; Tyler Beebe; Lan Wu; Nelson Jen; Eytan Wine; Chi-Hong Tseng; Jesus A Araujo; Alan Fogelman; Constantinos Sioutas; Mohamed Navab; Tzung K Hsiai Journal: Environ Health Perspect Date: 2014-08-29 Impact factor: 9.031